search
Back to results

Influence of Motor Proteins on Muscle Atrophy in Cancer Patients

Primary Purpose

Cancer, Muscle Atrophy

Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
whole-body electromyostimulation WB-EMS
Sponsored by
University of Erlangen-Nürnberg Medical School
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cancer focused on measuring Whole-body electromyostimulation, WB-EMS, Cancer, Muscle atrophy, Muscle protein, Exercise, Muscle fiber

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients ≥ 18 years
  • Solid pancreatic, colorectal, esophageal, gastric and liver tumors under oncological treatment
  • Karnofsky performance index between 50 and 100
  • Loss of body weight (≥ 2 % and < 5 %, weight before the illness and at study entry)
  • Distinct decrease in muscle force
  • Indication for surgery proximal to the M. rectus abdominis
  • Intervention Group must have an at least 8-week waiting period until the surgery (to conduct WB-EMS)

Exclusion Criteria:

  • Participation in other nutrition or exercise intervention studies
  • Study-independent exercise more than once a week
  • Ingestion of anabolic or dietary supplements
  • Occurrence of heavy cardio-vascular events
  • Epilepsy and other severe neurological disorders
  • Skin lesions in the area of the electrodes
  • Conductive materials or electronical implants in the body (that do not allow electromyostimulation)
  • Pregnancy
  • Chronic diseases (e.g. HIV or Hepatitis C/D/E)
  • Rejection of a muscle biopsy

Sites / Locations

  • Hector-Center for Nutrition, Exercise and SportsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

No Intervention

Experimental

Arm Label

Control group; patients without a tumor disease, surgery

Control group; tumor patients, surgery

Intervention group; tumor patients, WB-EMS, surgery

Arm Description

Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis

Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis

Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis

Outcomes

Primary Outcome Measures

Differences in Myosin:Actin ratio
Myosin:Actin ratio in the muscle biopsies assessed by protein analysis via Western Blotting.
Differences in Myosin isoforms
The Myosin isoforms in the muscle biopsies will be determined by protein expression analysis via Western Blotting.
Differences in cellular ultra structures
Cellular ultra structures in the muscle biopsies will be examined using multi-photon microscopy.
Differences in Force development and Calcium 2+ sensitivity of single muscle fibers
Force development and Calcium 2+ sensitivity of single muscle fibers from the muscle biopsies will be assessed by in situ biomechanical recording.
Differences in activation of involved signaling pathways
Signaling pathways that regulate muscle atrophy will be analyzed by examining protein expression and modification (Western Blotting), and gene expression (quantitative PCR) in the muscle biopsies.

Secondary Outcome Measures

Differences in inflammatory status
Pro-inflammatory cytokines
Differences in Nutritional risk
Nutritional Risk Screening-2002

Full Information

First Posted
May 10, 2017
Last Updated
May 28, 2018
Sponsor
University of Erlangen-Nürnberg Medical School
search

1. Study Identification

Unique Protocol Identification Number
NCT03551990
Brief Title
Influence of Motor Proteins on Muscle Atrophy in Cancer Patients
Official Title
Influence of Motor Proteins on Muscle Atrophy in Cancer Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
May 31, 2017 (Actual)
Primary Completion Date
December 2021 (Anticipated)
Study Completion Date
June 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Erlangen-Nürnberg Medical School

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of the study is to investigate the effect of exercise in form of whole-body electromyostimulation (WB-EMS) on early tumor-induced muscular dysfunction. It is anticipated to gain detailed knowledge about composition and metabolism of skeletal muscle cells, and single muscle fiber functionality. To determine key factors leading to impaired force generation and thus decreased muscle strength in cancer patients who are suspected to develop or already show early signs of tumor cachexia is crucial for the establishment of effective cancer treatment. Comparative analysis of skeletal muscle biopsies taken from the abdomen of patients during indicated surgeries will be conducted. The patients will be allocated to the following study groups: a) Study group 1: Patients without cancer, b) Study group 2: Patients with solid tumors who did not perform physical training and c) Study group 3: Patients with solid tumors who executed physical training in form of WB-EMS. The investigation can help to understand skeletal muscle physiology under exercise and to get a better insight into the effects of physical training on early-stage muscle atrophy, both on cellular and molecular level. Initially, it is planned to identify the inflammation and nutrition status of the patients, and to determine skeletal muscle strength. It is anticipated to explore muscle protein composition, particularly myosin to actin ratio and their interaction. Biochemical analysis and the examination of the cellular ultra-structure should enhance the knowledge about the key mechanisms controlling the contractile apparatus of single muscle fibers in order to determine the quality of muscle force. Taken together, these investigations will help to better understand muscle atrophy in advanced cancer patients, and might support the development of targeted anti-cachectic therapies, that can be applied already in early phases of the tumor disease to significantly improve the patients' prognosis and their quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer, Muscle Atrophy
Keywords
Whole-body electromyostimulation, WB-EMS, Cancer, Muscle atrophy, Muscle protein, Exercise, Muscle fiber

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
420 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control group; patients without a tumor disease, surgery
Arm Type
No Intervention
Arm Description
Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
Arm Title
Control group; tumor patients, surgery
Arm Type
No Intervention
Arm Description
Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
Arm Title
Intervention group; tumor patients, WB-EMS, surgery
Arm Type
Experimental
Arm Description
Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
Intervention Type
Procedure
Intervention Name(s)
whole-body electromyostimulation WB-EMS
Intervention Description
Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
Primary Outcome Measure Information:
Title
Differences in Myosin:Actin ratio
Description
Myosin:Actin ratio in the muscle biopsies assessed by protein analysis via Western Blotting.
Time Frame
8 weeks
Title
Differences in Myosin isoforms
Description
The Myosin isoforms in the muscle biopsies will be determined by protein expression analysis via Western Blotting.
Time Frame
8 weeks
Title
Differences in cellular ultra structures
Description
Cellular ultra structures in the muscle biopsies will be examined using multi-photon microscopy.
Time Frame
8 weeks
Title
Differences in Force development and Calcium 2+ sensitivity of single muscle fibers
Description
Force development and Calcium 2+ sensitivity of single muscle fibers from the muscle biopsies will be assessed by in situ biomechanical recording.
Time Frame
8 weeks
Title
Differences in activation of involved signaling pathways
Description
Signaling pathways that regulate muscle atrophy will be analyzed by examining protein expression and modification (Western Blotting), and gene expression (quantitative PCR) in the muscle biopsies.
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Differences in inflammatory status
Description
Pro-inflammatory cytokines
Time Frame
0 week
Title
Differences in Nutritional risk
Description
Nutritional Risk Screening-2002
Time Frame
0 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients ≥ 18 years Solid pancreatic, colorectal, esophageal, gastric and liver tumors under oncological treatment Karnofsky performance index between 50 and 100 Loss of body weight (≥ 2 % and < 5 %, weight before the illness and at study entry) Distinct decrease in muscle force Indication for surgery proximal to the M. rectus abdominis Intervention Group must have an at least 8-week waiting period until the surgery (to conduct WB-EMS) Exclusion Criteria: Participation in other nutrition or exercise intervention studies Study-independent exercise more than once a week Ingestion of anabolic or dietary supplements Occurrence of heavy cardio-vascular events Epilepsy and other severe neurological disorders Skin lesions in the area of the electrodes Conductive materials or electronical implants in the body (that do not allow electromyostimulation) Pregnancy Chronic diseases (e.g. HIV or Hepatitis C/D/E) Rejection of a muscle biopsy
Facility Information:
Facility Name
Hector-Center for Nutrition, Exercise and Sports
City
Erlangen
State/Province
Bavaria
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yurdagül Zopf, Prof. Dr. med.
Phone
+49 9131 85-45218
Email
yurdaguel.zopf@k-erlangen.de
First Name & Middle Initial & Last Name & Degree
Hans Joachim Herrmann, Dr. oec. troph.
Phone
+49 9131 85-45017
Email
hans.herrmann@uk-erlangen.de

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Influence of Motor Proteins on Muscle Atrophy in Cancer Patients

We'll reach out to this number within 24 hrs